SSG
ESPR

Summit Securities Group’s Esperion Therapeutics ESPR Stock Holding History

Summit Securities Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-412
Closed -$593 – 1176
2025
Q1 		$593 Buy
+412
New +$759 ﹤0.01% 717

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Summit Securities Group's ESPR Position: Q2 2025 in Review

Summit Securities Group sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 412 shares — an estimated $593 sold.

Summit Securities Group first reported a position in ESPR in Q1 2025 and held it in 1 quarter. The position peaked at $593 in Q1 2025. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Summit Securities Group reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 412 Esperion Therapeutics shares in Q2 2025, an estimated $593.
  • Summit Securities Group first reported a position in Esperion Therapeutics in Q1 2025 and held it in 1 quarter.
  • Summit Securities Group's Esperion Therapeutics position peaked at $593 in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.